Unlike CD33, CD123, and CLEC12A, FLT3 off-tumor expression is largely confined to a subset of HSPCs and is much lower than on malignant cells, which may provide a window for targeting AML without profound myeloablation.116. The gene discussed is CD33; the disease is neoplasm.